Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Fluvoxamine on BI 409306 PK
NCT02853136Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of osoresnontrine in schizophrenia and Alzheimer's disease (AD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 409306 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point and Maximum Measured Concentration of BI 409306 in Plasma. Started Aug 2016; status: completed.
02
Drugs
osoresnontrine
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02853136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853136.